3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
385
Myelodysplastic Syndromes
153
Leukemia, Myelomonocytic, Chronic
76
Leukemia
65
Recurrence
27
Hematologic Neoplasms
20
Myeloproliferative Disorders
18
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Anemia, Refractory, with Excess of Blasts
14
Neoplasms
13
Neoplasm, Residual
11
Multiple Myeloma
11
Leukemia, Monocytic, Acute
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Leukemia, Biphenotypic, Acute
11
Lymphoma, Non-Hodgkin
10
Leukemia, Myelomonocytic, Acute
10
Primary Myelofibrosis
9
Leukemia, Erythroblastic, Acute
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Myelodysplastic-Myeloproliferative Diseases
8
Lymphoma
8
Leukemia, Myeloid
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Leukemia, Megakaryoblastic, Acute
8
Congenital Abnormalities
8
Leukemia, Myelomonocytic, Juvenile
5
Hodgkin Disease
5
GATA2 Deficiency
5
Lymphoma, Large B-Cell, Diffuse
4
Interventions
midostaurin
3
avapritinib
2
ripretinib
1
obatoclax
1
nilotinib
1
ibrutinib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
denileukin diftitox
1
auricularum
1
Ranitidine
1
Interviews as Topic
1
Imatinib Mesylate
1
Ibuprofen
1
Diphenhydramine
1
Dexamethasone
1
Calcium Dobesilate
1
Brentuximab Vedotin
1
Azacitidine
1
Acetaminophen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mastocytosis, Systemic
×
Azacitidine
×
Other hematologic neoplasm
×
Clear all
NCT05609942
2025-04-10
AZURE
Blueprint Medicines Corporation
Phase 1
Terminated
9 enrolled